Jyong Biotech Ltd. Ordinary Shares cash flow to debt ratio of -16.39% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Jyong Biotech Ltd. Ordinary Shares's free cash flow has increased -16.09% from $-3.62M last year to $-3.04M, signaling increasing performance

Jyong Biotech Ltd. Ordinary Shares's debt to equity ratio is -0.74, signaling that the company spent its equity and risk bankruptcy.

Jyong Biotech Ltd. Ordinary Shares's debt to equity ratio is -0.74, signaling that the company spent its equity and risk bankruptcy.

Jyong Biotech Ltd. Ordinary Shares has negative EBITDA, making leverage ratio unreliable

Jyong Biotech Ltd. Ordinary Shares's interest coverage ratio is -1.03, which means that the company struggles to meet interest obligations, signaling financial risk.

Jyong Biotech Ltd. Ordinary Shares has insufficient data to evaluate this check.

Jyong Biotech Ltd. Ordinary Shares's short-term liabilities of $34.81M exceed its short-term assets of $15.54M, signaling financial risk

Jyong Biotech Ltd. Ordinary Shares's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Jyong Biotech Ltd. Ordinary Shares's return on equity of 19.39%, is higher than 15.00%, indicating good performance

Jyong Biotech Ltd. Ordinary Shares's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Jyong Biotech Ltd. Ordinary Shares has insufficient public price history to evaluate earnings stability.

Jyong Biotech Ltd. Ordinary Shares has negative free cash flow, indicating the company is burning cash rather than generating it

Jyong Biotech Ltd. Ordinary Shares has negative free cash flow, indicating cash burn

Jyong Biotech Ltd. Ordinary Shares's yearly earnings has decreased 54.72% since last year from $-3.02M to $-4.67M, signaling decreasing performance

Jyong Biotech Ltd. Ordinary Shares's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 46.00% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Jyong Biotech Ltd. Ordinary Shares has insufficient revenue history to calculate 3-year revenue CAGR.

Jyong Biotech Ltd. Ordinary Shares has insufficient public price history to evaluate revenue consistency.

Jyong Biotech Ltd. Ordinary Shares has insufficient public price history to evaluate ROE consistency.

Jyong Biotech Ltd. Ordinary Shares has insufficient data to evaluate this check.

Jyong Biotech Ltd. Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Jyong Biotech Ltd. Ordinary Shares is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Jyong Biotech Ltd. Ordinary Shares has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Jyong Biotech Ltd. Ordinary Shares has insufficient data to evaluate this check.

Jyong Biotech Ltd. Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Jyong Biotech Ltd. Ordinary Shares has negative shareholder equity; price-to-book is not meaningful and the check fails

Jyong Biotech Ltd. Ordinary Shares has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue